https://www.selleckchem.com/pr....oducts/Rapamycin.htm
The patient's history of primary biliary cirrhosis may be an important risk factor for the development of hepatotoxicity from exemestane. Hepatotoxicity with aromatase inhibitors have rarely been reported in clinical trials and to date, instances of exemestane induced hepatotoxicity has only been reported in two case reports. The patient's history of primary biliary cirrhosis may be an important risk factor for the development of hepatotoxicity from exemestane. Decades of research have examined immune-modulatory strategies to protect
Like
Comment
Share
